CY1112962T1 - 1,2-διαρυλο βενζιμιδαζολες για την αντιμετωπιση ασθενειων, οι οποιες σχετιζονται με την ενεργοποιηση μικρογλοιων - Google Patents

1,2-διαρυλο βενζιμιδαζολες για την αντιμετωπιση ασθενειων, οι οποιες σχετιζονται με την ενεργοποιηση μικρογλοιων

Info

Publication number
CY1112962T1
CY1112962T1 CY20111101101T CY111101101T CY1112962T1 CY 1112962 T1 CY1112962 T1 CY 1112962T1 CY 20111101101 T CY20111101101 T CY 20111101101T CY 111101101 T CY111101101 T CY 111101101T CY 1112962 T1 CY1112962 T1 CY 1112962T1
Authority
CY
Cyprus
Prior art keywords
activation
microglobe
bilzenimidazoles
disease treatment
benzimidazoles
Prior art date
Application number
CY20111101101T
Other languages
English (en)
Inventor
Joachim Kuhnke
Wolfgang Halfbrodt
Ursula Moenning
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of CY1112962T1 publication Critical patent/CY1112962T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η εφεύρεση σχετίζεται με 1, 2 - διαρυλο βενζιμιδαζόλες του γενικού τύπου (Ι) και με την χρήση παραγώγων βενζιμιδαζολών για την παρασκευή φαρμακευτικών προϊόντων, με σκοπό την θεραπεία και την προφύλαξη από ασθένειες, οι οποίες συνδέονται με μία ενεργοποίηση μικρογλοίων.
CY20111101101T 2000-01-14 2011-11-16 1,2-διαρυλο βενζιμιδαζολες για την αντιμετωπιση ασθενειων, οι οποιες σχετιζονται με την ενεργοποιηση μικρογλοιων CY1112962T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10002898 2000-01-14
EP01915133A EP1246808B1 (de) 2000-01-14 2001-01-12 1,2-diarylbenzimidazole zur behandlung von erkrankungen die mit einer microglia-aktivierung assoziiert sind

Publications (1)

Publication Number Publication Date
CY1112962T1 true CY1112962T1 (el) 2016-04-13

Family

ID=7628535

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101101T CY1112962T1 (el) 2000-01-14 2011-11-16 1,2-διαρυλο βενζιμιδαζολες για την αντιμετωπιση ασθενειων, οι οποιες σχετιζονται με την ενεργοποιηση μικρογλοιων

Country Status (31)

Country Link
EP (1) EP1246808B1 (el)
JP (1) JP2003523961A (el)
KR (1) KR100703908B1 (el)
CN (1) CN1301975C (el)
AT (1) ATE520669T1 (el)
AU (1) AU782993B2 (el)
BG (1) BG65858B1 (el)
BR (1) BR0107628A (el)
CA (1) CA2396227C (el)
CY (1) CY1112962T1 (el)
CZ (1) CZ303726B6 (el)
DK (1) DK1246808T3 (el)
EA (1) EA006302B1 (el)
EE (1) EE05515B1 (el)
ES (1) ES2372026T3 (el)
HR (1) HRP20020664B1 (el)
HU (1) HU228366B1 (el)
IL (2) IL150150A0 (el)
ME (1) MEP13308A (el)
MX (1) MXPA02005742A (el)
NO (1) NO326408B1 (el)
NZ (1) NZ519326A (el)
PL (1) PL209573B1 (el)
PT (1) PT1246808E (el)
RS (1) RS51860B (el)
SI (1) SI1246808T1 (el)
SK (1) SK287527B6 (el)
TW (1) TWI287005B (el)
UA (1) UA75589C2 (el)
WO (1) WO2001051473A1 (el)
ZA (1) ZA200206470B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855714B2 (en) 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
DE10134775A1 (de) * 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
DE10135050A1 (de) * 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US6903126B2 (en) 2001-07-09 2005-06-07 Schering Ag 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
US6962932B2 (en) 2002-02-15 2005-11-08 Schering Aktiengesellschaft 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
DE10207843A1 (de) * 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
DE10207844A1 (de) 2002-02-15 2003-09-04 Schering Ag 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
KR20050122210A (ko) * 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
SE0302570D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302573D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
KR101269869B1 (ko) 2004-09-24 2013-06-07 네오메드 인스티튜트 벤즈이미다졸 유도체, 그를 함유하는 조성물, 그의 제조방법 및 그의 용도
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
JP5255994B2 (ja) * 2008-11-04 2013-08-07 国立大学法人 岡山大学 核内受容体リガンド
EP2595482A4 (en) * 2010-07-21 2013-12-25 Merck Sharp & Dohme ALDOSTERONSYNTHASEHEMMER
CN102382102B (zh) * 2010-09-06 2014-01-08 中国科学院广州生物医药与健康研究院 一种酰胺类化合物
JP6200903B2 (ja) * 2012-02-17 2017-09-20 キネタ フォー エルエルシー アレナウイルス感染症の治療のための抗ウイルス薬
WO2014044611A1 (en) 2012-09-20 2014-03-27 Bayer Pharma Aktiengesellschaft 1-aryl-2-heteroaryl benzimidazoles for the induction of neuronal regeneration
WO2017106050A1 (en) * 2015-12-15 2017-06-22 The Board Of Trustees Of The Leland Stanford Junior University Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
AU2019353144B2 (en) 2018-10-05 2023-11-16 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4430502A (en) * 1982-08-13 1984-02-07 The Upjohn Company Pyridinyl substituted benzimidazoles and quinoxalines
ATE163290T1 (de) * 1991-06-24 1998-03-15 Neurosearch As Imidazol-verbindungen, verfahren zu ihrer herstellung und ihre anwendung
MX9203323A (es) * 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4330959A1 (de) * 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
PE27997A1 (es) * 1994-04-29 1997-09-20 Lilly Co Eli Antagonistas de receptores de taquicininas
AU6966696A (en) * 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1997033873A1 (en) * 1996-03-11 1997-09-18 Eli Lilly And Company Methods of treating or preventing interstitial cystitis

Also Published As

Publication number Publication date
KR100703908B1 (ko) 2007-04-05
WO2001051473A8 (de) 2002-01-03
AU782993B2 (en) 2005-09-15
PL209573B1 (pl) 2011-09-30
JP2003523961A (ja) 2003-08-12
SK10002002A3 (sk) 2003-02-04
ES2372026T3 (es) 2012-01-13
MEP13308A (en) 2010-10-10
HRP20020664B1 (en) 2012-03-31
KR20020063629A (ko) 2002-08-03
TWI287005B (en) 2007-09-21
BR0107628A (pt) 2002-10-08
UA75589C2 (en) 2006-05-15
NO326408B1 (no) 2008-12-01
HRP20020664A2 (en) 2005-04-30
MXPA02005742A (es) 2002-09-18
EP1246808B1 (de) 2011-08-17
ATE520669T1 (de) 2011-09-15
CN1301975C (zh) 2007-02-28
HU228366B1 (en) 2013-03-28
IL150150A (en) 2014-03-31
CA2396227C (en) 2012-03-20
PT1246808E (pt) 2011-11-30
CZ20022420A3 (cs) 2002-10-16
WO2001051473A1 (de) 2001-07-19
EA200200742A1 (ru) 2002-12-26
SI1246808T1 (sl) 2011-12-30
HUP0204011A2 (en) 2003-05-28
DK1246808T3 (da) 2011-12-05
EA006302B1 (ru) 2005-10-27
EP1246808A1 (de) 2002-10-09
IL150150A0 (en) 2002-12-01
NO20023362L (no) 2002-09-13
AU4233201A (en) 2001-07-24
NO20023362D0 (no) 2002-07-12
PL356091A1 (en) 2004-06-14
EE05515B1 (et) 2012-02-15
SK287527B6 (sk) 2011-01-04
EE200200390A (et) 2003-10-15
NZ519326A (en) 2005-02-25
CA2396227A1 (en) 2001-07-19
YU45702A (sh) 2005-03-15
CZ303726B6 (cs) 2013-04-10
ZA200206470B (en) 2004-04-28
CN1395568A (zh) 2003-02-05
HUP0204011A3 (en) 2003-07-28
BG106821A (bg) 2003-01-31
BG65858B1 (bg) 2010-03-31
RS51860B (sr) 2012-02-29

Similar Documents

Publication Publication Date Title
CY1112962T1 (el) 1,2-διαρυλο βενζιμιδαζολες για την αντιμετωπιση ασθενειων, οι οποιες σχετιζονται με την ενεργοποιηση μικρογλοιων
CY1106890T1 (el) Παραγωγα της ακριδινης και η χρηση τους ως φαρμακων
CY1110019T1 (el) Συνδυασμενη θεραπεια με υποκατεστημενες οξαζολιδινονες
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
CY1108274T1 (el) Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων
CY1109422T1 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
CY1107615T1 (el) Θεραπευτικοι συνδυασμοι αντιυπερτασικων και αντιαγγειογενετικων παραγοντων
CY1110721T1 (el) Χρηση glp-2 σε συνδυασμο με αλλο θεραπευτικο παραγοντα σε οστικες παθησεις
CY1110405T1 (el) Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων
CY1105286T1 (el) Ω-καρβοξυαρυλυποκατεστημενες διφαινυλουριες σαν αναστολεις της raf κινασης
ATE408601T1 (de) Fredericamycin-derivate
CY1115580T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξικης πιπεραζινης
CY2013004I1 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας
BR0012793A (pt) Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
ES2192839T3 (es) Timosina beta 4 oxidada.
CY1111902T1 (el) Χρηση ακυλοφωσφοχολινων σε συνδυασμο με αντινεοπλασματικα φαρμακα
ATE433989T1 (de) Pharmazeutisch wirksame uridinester
ATE400577T1 (de) Anellierte dihydropyrane
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
CY1112740T1 (el) ΧΡΗΣΗ ΔΕΝΔΡΙΤΙΚΩΝ ΚΥΤΤΑΡΩΝ (DCs) ΕΚΦΡΑΖΟΝΤΑΣ ΙΝΤΕΡΛΕΥΚΙΝΗ 12 (IL-12)
DK1992338T3 (da) Pharmaceutical compositions for the oral administration of heparin or derivatives thereof